Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Performance of a New Implant System for Bone Conduction Hearing

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03086135
Recruitment Status : Completed
First Posted : March 22, 2017
Results First Posted : February 5, 2020
Last Update Posted : February 5, 2020
Sponsor:
Information provided by (Responsible Party):
Cochlear Bone Anchored Solutions

Brief Summary:
To study the initial experience with implanting and fitting the new Bone conduction system in patients with conductive, mixed or Single sided Sensorineural deafness.

Condition or disease Intervention/treatment Phase
Deafness; Sensoneural Single Sided Conductive Hearing Loss Mixed Hearing Loss Device: Osia System Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 51 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Performance of a New Implant System for Bone Conduction Hearing
Actual Study Start Date : March 9, 2017
Actual Primary Completion Date : October 30, 2018
Actual Study Completion Date : June 20, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Bone-conduction hearing device
The bone-conduction hearing device Osia system allows a direct bone-conduction through an osseointegrated implant. A magnet allows the external Sound Processor to be placed in the correct position over the implanted system including an inner magnet.
Device: Osia System
An external Sound Processor captures and digitize the sound which is transferred to the internal implant where it is converted to an electrical signal. The electrical signal is further transferred as a vibration through an osseointegrated implant to the mastoid bone and eventually to the cochlea.




Primary Outcome Measures :
  1. Hearing Performance: Threshold Audiometry, Pure Tone Average of 4 Frequencies, PTA4, Unaided Versus OSIA System at 3 Months [ Time Frame: Baseline before surgery, 3 months after surgery ]
    The change of hearing performance from the unaided hearing situation before surgery to the aided hearing situation with the OSIA system at 3 month, measured as free-field hearing test; Threshold audiometry PTA4 (mean of 500, 1000, 2000 and 4000 Hz) is presented. A Pure Tone Average (PTA) refers to the average of hearing threshold levels at a set of specified frequencies: typically 500, 1000, 2000 and 4000 Hz. This value gives a snapshot of an individual's hearing level. If PTA is <25 dB, the overall hearing would be considered to be within normal limits. With a PTA of 95 dB, the hearing would be considered in the profound range. The units reported for PTA4 are decibels (dB). The results presented here are the difference of PTA4 unaided and PTA4 aided with the Osia system. An uaided PTA4 values should be higher than a aided PTA4 if the hearing device is effective. A lower or more negative score is more desirable and reflects a better ability to hear softer sounds.

  2. Adaptive Speech Recognition in Noise, Unaided Versus OSIA System at 3 Months. [ Time Frame: Baseline before surgery, 3 months after surgery ]
    The change of hearing performance from the unaided hearing situation before surgery to the aided hearing situation with the OSIA System at 3 months measured as free field hearing test Adaptive speech recognition in noise, is presented. Adaptive speech recognition in noise was measured as Signal to Noise Ratio (SNR). The noise was kept constant at 65 dB SPL and the speech was adapted in dB steps to establish the Speech-to-Noise Ratio (SNR) providing a 50% level of understanding. A ratio of 0 reflects the ability to correctly hear sentences at 65 dB, in the presence of 65 dB background noise. A negative SNR-value reflects the ability to correctly hear sentences below 65 dB, for example if 50% of the speech is received correctly at 55 dB the SNR value is -10. A positive SNR-value (Speech to Noise Ratio) reflects the ability to correctly hear sentences presented above 65 dB. A lower or more negative score is more desirable and reflects abetter hearing in a noisy enviroment.


Secondary Outcome Measures :
  1. Hearing Performance: Threshold Audiometry, Pure Tone Average, PTA4, Unaided Versus OSIA System at 4 Weeks, 6 and 12 Months [ Time Frame: Baseline before surgery, 4 weeks, 6 and 12 months after surgery ]
    The change of hearing performance from the unaided hearinhg situation before surgery to the aided hearing situation with the OSIA system at 4 weeks, 6 and 12 months, measured as free-field hearing test: Threshold audiometry PTA4 (mean of 500, 1000, 2000 and 4000 Hz) is presented. A Pure Tone Average (PTA) refers to the average of hearing threshold levels at a set of specified frequencies: typically 500, 1000, 2000 and 4000 Hz. This value gives a snapshot of an individual's hearing level. If PTA is <25 dB, the overall hearing would be considered to be within normal limits. With a PTA of 95 dB, the hearing would be considered in the profound range. The units reported for PTA4 are decibels (dB). The results presented here are the difference of PTA4 unaided and PTA4 aided with the Osia system. An uaided PTA4 values should be higher than a aided PTA4 if the hearing device is effective. A lower or more negative score is more desirable and reflects a better ability to hear softer sounds.

  2. Hearing Performance: Threshold Audiometry Individual Frequences, Unaided Versus OSIA System at 4 Weeks, 3, 6 and 12 Months [ Time Frame: Baseline before surgery, 4 weeks, 3, 6 and 12 months after surgery. ]
    The change of hearing performance from the unaided hearing situation before surgery to the aided hearing situation with the OSIA system at 4 weeks, 3, 6 and 12 months, measured as free-field hearing test: Threshold audiometry (0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0 and 8.0 kHz) is presented. This value gives a snapshot of an individual's hearing level. If PTA is <25 dB, the overall hearing would be considered to be within normal limits. With a PTA of 95 dB, the hearing would be considered in the profound range. The units reported for PTA4 are decibels (dB). The results presented here are the difference of the unaided hearing level expressed in dB and the hearing level aided with the Osia system at different time points. An unaided value should be higher than a aided if the hearing device is effective. A lower or more negative score is therefor more desirable and reflects a better ability to hear at the specified frequency.

  3. Speech in Quiet at 50, 65 and 80 dB SPL, Unaided Versus OSIA System at 4 Weeks, 3, 6 and 12 Months [ Time Frame: Baseline before surgery, 4 weeks, 3, 6 and 12 months after surgery. ]
    The change of hearing performance from the unaided hearing situation before surgery to the aided hearing situation with the OSIA System at 4 weeks, 3, 6 and 12 months, measured as free-field hearing test Speech in quiet at 50, 65 and 80 dB SPL [% correctly perceived words at 50, 65 and 80 dB SPL] is presented. The change in percent points is presented. A positive value indicates an improved ability to perceive words in quiet at the specified decibel (dB) level a negative value represent an impairment.

  4. Adaptive Speech Recognition in Noise, Unaided Versus OSIA System at 4 Weeks, 6 and 12 Months [ Time Frame: Baseline before surgery, 4 weeks, 6 and 12 months after surgery ]
    The change of hearing performance from the unaided hearing situation before surgery to the aided hearing situation with the OSIA System at 3 months measured as free field hearing test Adaptive speech recognition in noise, is presented. Adaptive speech recognition in noise was measured as Signal to Noise Ratio (SNR). The noise was kept constant at 65 dB SPL and the speech was adapted in dB steps to establish the Speech-to-Noise Ratio (SNR) providing a 50% level of understanding. A ratio of 0 reflects the ability to correctly hear sentences at 65 dB, in the presence of 65 dB background noise. A negative SNR-value reflects the ability to correctly hear sentences below 65 dB, for example if 50% of the speech is received correctly at 55 dB the SNR value is -10. A positive SNR-value (Speech to Noise Ratio) reflects the ability to correctly hear sentences presented above 65 dB. A lower or more negative score is more desirable and reflects a better hearing in a noisy environment.

  5. Abbreviated Profile of Hearing Aid Benefit (APHAB) at 3 and 12 Months [ Time Frame: Baseline before surgery, 3 and 12 months after surgery ]
    The change of Ease of communication, Reverberation, Background noise, Aversiveness and a Global score from the unaided hearing situation before surgery to the aided hearing situation with the OSIA System at 3 and 12 months is presented. All subscales range from 0-100%, total score is the average of all subscales 0-100%, where 0% indicates no problem and 100% indicates always problem. The difference between the unaided and the aided situation is presented. In an ultimate case the unaided value could be 100 and the aided 0, the result is then 100. A positive value indicates an improvement, a negative value an impairment.

  6. Health Utility Index (HUI) at 3 and 12 Months [ Time Frame: Baseline before surgery and 3 and 12 months after surgery ]
    The change of health status and health related quality of life from the unaided hearing situation before surgery to the aided hearing situation with the OSIA System at 3 and 12 months using the generic quality of life scale Health Utilities Index (HUI3) is presented. All subscales (comprehensive health state, vision, hearing, speech, ambulation, dexterity, emotion, pain, cognition) range from 0-1. A health utility value of 1.00 indicates perfect health while a score of 0.00 indicates death. The difference between the unaided and the aided situation is presented. In an ultimate case the unaided value could be 0 and the aided 1, the result is then 1.0. A positive value indicates an improved quality of life, a negative value indicates impaired quality of life.

  7. Speech, Spatial and Qualities of Hearing Scale (SSQ) at 3 and 12 Months [ Time Frame: Baseline before surgery and 3 and 12 months after surgery ]
    The change of speech, spatial and hearing experiences from the unaided hearing situation before surgery to the aided hearing situation with the OSIA System at 3 and 12 months using the SSQ scale is presented. All subscales (speech, spatial, quality) range from 0 to 10, where 0 represents "can not hear at all", and 10 "hear perfectly". Total score is a average of the subscales. A positive value indicates improved hearing, a negative value indicates impaired hearing.

  8. Hearing Performance: Threshold Audiometry PTA4, With Reference Device BP110 [ Time Frame: Baseline before surgery, 4 weeks, 3, 6 and 12 months. ]
    The change of hearing performance with the OSIA System at 4 weeks, 3, 6 and 12 months compared to the pre-operative aided situation with BP110 on softband, measured as free-field hearing test; Threshold audiometry PTA4 (mean of 500, 1000, 2000 and 4000 Hz) is presented. The units reported for PTA4 are decibels (dB). A lower or more negative score is more desirable and reflects a better ability to hear softer sounds.

  9. Hearing Performance: Threshold Audiometry Individual Frequences With Reference Device BP110 [ Time Frame: Baseline before surgery, 4 weeks, 3, 6 and 12 months after surgery. ]
    The change of hearing performance with the OSIA System at 4 weeks, 3, 6 and 12 months compared to the pre-operative aided situation with BP110 on softband, measured as free-field hearing test; Threshold audiometry individual frequencies (0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0 and 8.0 kHz) is presented. The units reported are decibels (dB). A lower or more negative score is more desirable and reflects a better ability to hear softer sounds.

  10. Speech in Quiet at 50, 65 and 80 dB SPL, With Reference Device BP110 [ Time Frame: Baseline before surgery, 4 weeks, 3, 6 and 12 months after surgery. ]
    The change of hearing performance with the OSIA System at 4 weeks, 3, 6 and 12 months compared to the pre-operative aided situation with BP110 on softband measured as free-field hearing test; Speech in quiet [% correctly perceived words at 50, 65 and 80 dB SPL]. The change in percent points is presented. A positive value indicates an improved ability to perceive words in quiet at the specified decibel (dB) level a negative value represent an impairment.

  11. Adaptive Speech Recognition in Noise, With Reference Device BP110 [ Time Frame: Baseline before surgery, 4 weeks, 3, 6 and 12 months after surgery. ]
    The change of hearing performance with the OSIA System at 4 weeks, 3, 6 and 12 months compared to the pre-operative aided situation with BP110 on softband;measured with free field hearing test Adaptive speech recognition in noise which was measured as signal to noise ratio (SNR). The noise was kept constant at 65 dB SPL and the speech was adapted in dB steps to establish the speech-to-noise ratio (SNR) providing a 50% level of understanding. A ratio of 0 reflects the ability to correctly hear sentences at 65 dB, in the presence of 65 dB background noise. A negative SNR-value reflects the ability to correctly hear sentences below 65 dB. A positive SNR-value reflects the ability to correctly hear sentences presented above 65 dB. A lower or more negative score is more desirable and represent a better hearing in a noisy environment.

  12. Surgical Information: Time of Surgery [ Time Frame: Visit 2, surgery ]
    Surgery time in minutes between first incision and last suture

  13. Soft Tissue Thickness [ Time Frame: Visit 2, surgery ]
    Surgical information: Soft tissue thickness was measured in mm

  14. Soft Tissue Reduction [ Time Frame: Visit 2, surgery ]
    Surgical information: a question was asked if soft tissue reduction had been performed. Could be answered by ticking a box for "Yes" or "No".

  15. Bone Polishing/Removal at Implant Site [ Time Frame: Visit 2, surgery ]
    Surgical information: a question is asked if bone polishing/removal at Implant site has been performed. Yes or No can be ticked.

  16. Type of Anaesthesia [ Time Frame: Visit 2, surgery ]
    Surgical information: a question is asked which type of anaesthesia has been used: local or general can be ticked.

  17. Location of BI300 Implant [ Time Frame: Visit 2, surgery ]

    Surgical information: where is the location of the BI300 implant, measured in two different ways:

    Alternative 1 used for the first 6 subjects: Location from the ear channel in mm.

    Alternative 2 used for the rest of the population 45 subjects, after an amendment: measured in mm horizontally and vertically from ear channel. and the distance in mm between the receiver and the coil.

    Value 9.64 mm vertically from ear channel is correct.


  18. Incision Type [ Time Frame: Visit 2, surgery ]
    Surgical information: a question was asked regarding what type of incision had been used; C-shaped flap, posterior based flap or other could be ticked.

  19. Daily Usage Time of Sound Processor [ Time Frame: 6 weeks, 3, 6 and 12 months ]
    Sound processor usage time measured as hours per day.

  20. Comfort [ Time Frame: 6 weeks, 3, 6 and 12 months ]
    Comfort of sound processor measured with a visual analogue scale where 0% is defined as no comfort at all and 100% as most comfortable imaginable, i.e. minimum 0, maximum 100.

  21. Magnet Choice [ Time Frame: 4, 6 weeks, 3, 6 and 12 months ]
    Available magnet strengths: 1/2, 1, 2, 3, 4, 5 or 6, where 1/2 is the weakest and 6 the strongest.

  22. Softpad Use [ Time Frame: 6 weeks, 3, 6 and 12 months ]
    A question was asked if the subjects used softpads; yes or no could be ticked.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Adult subjects (18 years or older)
  • Subject with conductive or mixed hearing loss in the ear to be implanted. Bone conduction thresholds with pure tone average (PTA4; mean of 0.5, 1, 2 and 4 kHz) of 55 dB HL.

OR Subject with single-sided sensorineural deafness who is a candidate for Baha surgery. Air conduction thresholds with a pure tone average PTA4 of 20 dB HL (mean of 0.5, 1, 2 and 3 kHz) in the good ear OR subject who is indicated for an AC CROS but—for some reason—cannot or will not use an AC CROS (Air Conduction-Contralateral Routing of Signal).

  • Signed informed consent
  • Previous experience from amplified sound though a non-surgical solution. (For example but not limited to Hearing aid, CROS device, Bone conductional hearing device on headband/ softband)

Exclusion Criteria:

  • Uncontrolled diabetes as judged by the investigator.
  • Condition that could jeopardise osseointegration and/or wound healing (e.g. osteoporosis, psoriasis, long-term systemic use of corticosteroids) or condition that may have an impact on the outcome of the investigation as judged by the investigator.
  • Insufficient bone quality and quantity for implantation of a BI300 Implant.
  • Subject that has received radiotherapy in the area of implantation, or is planned for such radiotherapy during the study period
  • Use of ototoxic drugs that could be harmful to the hearing, as judged by the investigator
  • Unable to follow investigational procedures, e.g. to complete quality of life scales.
  • Participation in another clinical investigation with pharmaceutical and/or device.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03086135


Locations
Layout table for location information
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109
Australia, Victoria
The Royal Victorian Eye and Ear Hospital
East Melbourne, Victoria, Australia, VIC 3002
Germany
University Medical Center Freiburg
Freiburg, Baden-Württemberg, Germany, 79106
Netherlands
Radboud University Medical Center
Nijmegen, Netherlands
Poland
World Hearing Center Institute of Physiology and Pathology of Hearing
Kajetany, Nadarzyn, Poland, 05-830
Sponsors and Collaborators
Cochlear Bone Anchored Solutions
Investigators
Layout table for investigator information
Principal Investigator: Emmanuel Mylanus, Prof. Radboud Univerity Medical centre
Principal Investigator: Robert Briggs, Prof. The Royal Victorian Eye and Ear Hospita
Principal Investigator: Susan Arndt, Prof. Universitätsklinikum Freiburg
Principal Investigator: Piotr Skarżyński, Ass.Prof. Center of Hearing and Speech
Principal Investigator: Henry Alexander Arts, Prof. University of Michigan
  Study Documents (Full-Text)

Documents provided by Cochlear Bone Anchored Solutions:
Study Protocol  [PDF] August 14, 2017
Statistical Analysis Plan  [PDF] April 16, 2018

Layout table for additonal information
Responsible Party: Cochlear Bone Anchored Solutions
ClinicalTrials.gov Identifier: NCT03086135    
Other Study ID Numbers: CBAS5539
First Posted: March 22, 2017    Key Record Dates
Results First Posted: February 5, 2020
Last Update Posted: February 5, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hearing Loss
Deafness
Hearing Loss, Conductive
Hearing Loss, Mixed Conductive-Sensorineural
Hearing Loss, Sensorineural
Hearing Disorders
Ear Diseases
Otorhinolaryngologic Diseases
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms